Impact of multidrug resistance on the pathogenicity of Pseudomonas aeruginosa: in vitro and in vivo studies.
暂无分享,去创建一个
A. Oliver | J. Ariza | F. Tubau | M. Camoez | M. Domínguez | C. Juan | G. Cabot | C. Peña | S. Gómez-Zorrilla | M. Domínguez
[1] A. Oliver,et al. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] Ronald N. Jones,et al. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries. , 2014, The Journal of antimicrobial chemotherapy.
[3] S. Lory,et al. Enhanced in vivo fitness of carbapenem-resistant oprD mutants of Pseudomonas aeruginosa revealed through high-throughput sequencing , 2013, Proceedings of the National Academy of Sciences.
[4] M. Toleman,et al. Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. , 2013, The Lancet. Infectious diseases.
[5] A. Oliver,et al. Biological Markers of Pseudomonas aeruginosa Epidemic High-Risk Clones , 2013, Antimicrobial Agents and Chemotherapy.
[6] N. Marx,et al. Inflammatory parameters and prediction of prognosis in infective endocarditis , 2013, BMC Infectious Diseases.
[7] Zhen-Zhen Sun,et al. Antibiotic Resistance in Pseudomonas Aeruginosa is Associated with Decreased Fitness , 2013, Cellular Physiology and Biochemistry.
[8] J. Ariza,et al. Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality , 2013, European Journal of Clinical Microbiology & Infectious Diseases.
[9] A. Oliver,et al. Genetic Markers of Widespread Extensively Drug-Resistant Pseudomonas aeruginosa High-Risk Clones , 2012, Antimicrobial Agents and Chemotherapy.
[10] M. Falagas,et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[11] L. Hansen,et al. Fitness cost: a bacteriological explanation for the demise of the first international methicillin-resistant Staphylococcus aureus epidemic. , 2012, The Journal of antimicrobial chemotherapy.
[12] A. Oliver,et al. Prospective Multicenter Study of the Impact of Carbapenem Resistance on Mortality in Pseudomonas aeruginosa Bloodstream Infections , 2011, Antimicrobial Agents and Chemotherapy.
[13] A. Oliver,et al. A large sustained endemic outbreak of multiresistant Pseudomonas aeruginosa: a new epidemiological scenario for nosocomial acquisition , 2011, BMC infectious diseases.
[14] V. Tam,et al. Effect of multidrug resistance-conferring mutations on the fitness and virulence of Pseudomonas aeruginosa. , 2011, The Journal of antimicrobial chemotherapy.
[15] T. Tsaganos,et al. Impact of Multidrug Resistance on Experimental Empyema by Pseudomonas aeruginosa , 2011, Respiration.
[16] R. López-Rojas,et al. Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. , 2011, The Journal of infectious diseases.
[17] V. Tam,et al. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes , 2010, Expert review of pharmacoeconomics & outcomes research.
[18] Sebastian Bonhoeffer,et al. Compensation of Fitness Costs and Reversibility of Antibiotic Resistance Mutations , 2010, Antimicrobial Agents and Chemotherapy.
[19] Diarmaid Hughes,et al. Antibiotic resistance and its cost: is it possible to reverse resistance? , 2010, Nature Reviews Microbiology.
[20] Zixin Deng,et al. Pathogenicity Islands PAPI-1 and PAPI-2 Contribute Individually and Synergistically to the Virulence of Pseudomonas aeruginosa Strain PA14 , 2010, Infection and Immunity.
[21] A. Oliver,et al. Nosocomial Outbreak of a Non-Cefepime-Susceptible Ceftazidime-Susceptible Pseudomonas aeruginosa Strain Overexpressing MexXY-OprM and Producing an Integron-Borne PSE-1 ß-Lactamase , 2009, Journal of Clinical Microbiology.
[22] J. Engel,et al. Role of Pseudomonas aeruginosa type III effectors in disease. , 2009, Current opinion in microbiology.
[23] D. Scholl,et al. Antibacterial Efficacy of R-Type Pyocins towards Pseudomonas aeruginosa in a Murine Peritonitis Model , 2008, Antimicrobial Agents and Chemotherapy.
[24] S. Cosgrove. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] E. D. Gol’dberg,et al. Immunity Parameters in Mice of Different Strains , 2005, Bulletin of Experimental Biology and Medicine.
[26] R. Summerbell,et al. Fusarium verticillioides Abscess of the Nasal Septum in an Immunosuppressed Child: Case Report and Identification of the Morphologically Atypical Fungal Strain , 2005, Journal of Clinical Microbiology.
[27] J. Vincent,et al. Molecular Characterization of an Epidemic Clone of Panantibiotic-Resistant Pseudomonas aeruginosa , 2005, Journal of Clinical Microbiology.
[28] H. Grundmann,et al. Development of a Multilocus Sequence Typing Scheme for the Opportunistic Pathogen Pseudomonas aeruginosa , 2004, Journal of Clinical Microbiology.
[29] E. Giamarellos‐Bourboulis,et al. Experimental sepsis using Pseudomonas aeruginosa: the significance of multi-drug resistance. , 2004, International journal of antimicrobial agents.
[30] Martin C. J. Maiden,et al. mlstdbNet – distributed multi-locus sequence typing (MLST) databases , 2004, BMC Bioinformatics.
[31] E. Giamarellos‐Bourboulis,et al. Stimulation of innate immunity by susceptible and multidrug‐resistant Pseudomonas aeruginosa: an in vitro and in vivo study , 2004, Clinical and experimental immunology.
[32] R. Hancock,et al. Multidrug Efflux Systems Play an Important Role in the Invasiveness of Pseudomonas aeruginosa , 2002, The Journal of experimental medicine.
[33] A. Hauser,et al. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. , 2001, Microbiology.
[34] Claude Carbón,et al. Relationship between Capsular Type, Penicillin Susceptibility, and Virulence of Human Streptococcus pneumoniae Isolates in Mice , 2000, Antimicrobial Agents and Chemotherapy.
[35] N. Barekzi,et al. Efficacy of Locally Delivered Polyclonal Immunoglobulin against Pseudomonas aeruginosa Peritonitis in a Murine Model , 1999, Antimicrobial Agents and Chemotherapy.
[36] D H Persing,et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing , 1995, Journal of clinical microbiology.
[37] A. Deptuła,et al. Reduced expression of virulence factors in multidrug-resistant Pseudomonas aeruginosa strains , 2009, Archives of Microbiology.
[38] A. Hauser,et al. Interactions between effector proteins of the Pseudomonas aeruginosa type III secretion system do not significantly affect several measures of disease severity in mammals. , 2006, Microbiology.
[39] N. Frimodt-Møller. The mouse peritonitis model: present and future use. , 1993, The Journal of antimicrobial chemotherapy.